What BIOTEM does

BIOTEM (legal entity SOCIETE DE SYSTEMES BIOLOGIEMES BIOTEM) is a France-based, privately-held Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) founded in 1980 and headquartered in the Isère department. The company provides custom antibody development, recombinant production, and immunoassay (ELISA and LFIA) services to almost 500 industrial and academic laboratories worldwide, executing more than 150 antibody development projects per year. BIOTEM serves three primary customer segments: research and academic laboratories requiring antibodies for ELISA, WB, FACS, IF, IHC, IP and functional assays; diagnostics companies building IVD kits under ISO 13485:2016; and therapeutic/biopharma companies needing humanized, chimeric, fully human, or species-tailored (caninized, felinized) antibodies for drug development.

The company's technical platform spans hybridoma and phage display discovery, in silico and wet-lab humanization (Ultimate Humanization® platform with guaranteed Germinality Index >92%), synthetic recombinant antibody libraries (Quinthetic Library™ for humanized VHH and fully human scFv), CHO-based recombinant production using both transient transfection and piggyBac™ transposon-derived stable cell pools, and IHC-specific workflows (IHC Peptide Profiler®, IHC Protein Formulations, R.A.D® rapid hybridoma protocol). BIOTEM also offers antibody characterization (sequencing, affinity by BLI/SPR, epitope mapping, stability), modification (conjugation, fragmentation, affinity maturation), and flow cytometry-based functional screening. The firm is certified to ISO 9001:2015 and ISO 13485:2016, holds French animal facility approval, and benefits from Crédit Impôt Recherche accreditation that allows clients to claim up to 50% R&D tax credit on project costs.

BIOTEM operates on a fee-for-service basis, charging project-based pricing with results-commitment contracts (featuring Go/No-Go milestones) on a large proportion of engagements. Critically, the company does not claim intellectual property rights on antibodies developed under fee-for-service projects, positioning itself as a pure-play service provider rather than an IP licensor. Revenue is generated through four primary streams: custom antibody development, recombinant antibody production and purification, immunoassay development and industrial-scale manufacturing, and catalog antibody/rapid test (Disp&FLOW®) sales. The go-to-market is direct sales-led, supported by a corporate website, scientific conference participation, and published testimonials from named therapeutic and diagnostic customers including Innate Pharma, Ose Immunotherapeutics, Rhythm Biosciences, Cyron Therapeutics, Dianova, and SATT Nord.

Name

BIOTEM

Legal name

SOCIETE DE SYSTEMES BIOLOGIQUES BIOTEM

Website

https://biotem-antibody.com

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

11–50 employees

Short description

BIOTEM is a French privately-held CRO/CMO founded in 1980 that develops custom monoclonal and polyclonal antibodies, recombinant antibody production, and ELISA/LFIA immunoassays for ~500 academic and industrial laboratories, serving research, diagnostics, and therapeutic biopharma customers via fee-for-service contracts.

Ownership category

akta.pro rank

Product category

Antibody Development and Immunoassay Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)

akta.pro secondary industries

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Custom antibody development
• Monoclonal antibody production
• Therapeutic antibody humanization
• ELISA LFIA development
• Recombinant antibody engineering

Headquarters

HQ city

Apprieu

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Fee-for-service antibody development: Custom monoclonal and polyclonal antibody development services charged on a fee-for-service basis. BIOTEM does not claim any intellectual property or other rights on results obtained in fee-for-service projects.
2. Antibody production and purification: Large-scale antibody production from hybridomas or sequences using CHO cells. Production scales from milligram to several grams with various purity and endotoxin level options.
3. Immunoassay development and production: ELISA and LFIA (Lateral Flow Immunoassay) development and industrial production services, including rapid tests (Disp&FLOW®).
4. Antibody catalog products: Sale of catalog antibodies and rapid tests products.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

BIOTEM is a hybrid Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) that, since 1980, has provided fee-for-service custom monoclonal and polyclonal antibody development, antibody engineering (humanization, chimerization, caninization, felinization), recombinant antibody production in CHO cells, and ELISA/LFIA immunoassay development and industrial-scale manufacturing. The company delivers these services to industrial and academic laboratories through project-based contracts, including results-commitment agreements with Go/No-Go milestones, without claiming intellectual property on developed antibodies.

Product overview

BIOTEM is a hybrid Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) providing antibody production and immunoassay services since 1980. The company operates three main service areas: Custom Antibody Production (monoclonal and polyclonal antibodies for research, diagnostics, and therapeutics), Immunoassays (ELISA and LFIA development and production), and BIOTEM Products (antibody catalogue and rapid tests including Disp&FLOW®). The product portfolio spans antibody discovery via hybridoma and phage display technologies, antibody engineering (humanization, chimerization, caninization, felinization), recombinant production platforms (transient and stable CHO cell systems), and immunoassay development. Key proprietary technologies include Quinthetic Library™ synthetic antibody libraries, Ultimate Humanization® platform with guaranteed Germinality Index, IHC Peptide Profiler®, and Flow Cytometry screening platforms.

Differentiator

Problem solved

Functional benefit

Brands

• Quinthetic Library™: Synthetic antibody library platform developed by BIOTEM scientists T. Pelat and A. Guellouz for generating recombinant antibodies with optimized CDR and Vernier residue variability.
• IHC Peptide Profiler®
• Ultimate Humanization®
• R.A.D® Protocol
• S.S.I. Protocol
• Disp&FLOW®

Products and services

• Custom Antibody Production End-to-end fee-for-service for the development, production, modification and characterization of high-quality monoclonal and polyclonal antibodies using hybridoma technology and phage display, for industrial and academic customers.
• Mouse & Rat Monoclonal Antibodies Custom development and production of mouse and rat monoclonal antibodies via Hybridoma or Phage Display technologies for research, diagnostic and therapeutic applications.
• Rabbit Monoclonal Antibodies Custom rabbit monoclonal antibody production via phage display, providing high-affinity and high-specificity reagents for research and diagnostic applications.
• Quinthetic Library™ Synthetic Libraries Ready-to-use VHH Quinthetic Library™ (humanized VHH) and scFv Quinthetic Library™ (fully human scFv) synthetic antibody libraries for rapid antibody discovery against toxic, poorly immunogenic, or highly conserved targets as an alternative to immunization.
• Flow Cytometry Antibodies Custom monoclonal antibody development that incorporates BIOTEM's Flow Cytometry platform for functional screening and identification of antibodies through project stages.
• IHC Antibodies Immunohistochemistry monoclonal antibody development optimized for formalin-fixed paraffin-embedded (FFPE) specimens using IHC Peptide Profiler® and tailored IHC Protein Formulations.
• Polyclonal Antibodies Custom polyclonal antibody production in rabbits, guinea pigs, goats, mice, rats, chickens and other species using customized protocols for research and diagnostic applications.
• Fully Human Antibodies Generation of 100% human monoclonal antibodies from immune libraries of immunized human donors, via phage display or EBV immortalization, for therapeutic discovery programs.
• Ultimate Humanization® Platform Exclusive therapeutic antibody humanization service combining NHP immunization, phage display screening and germinalization to deliver humanized antibodies with a guaranteed Germinality Index above 92% while retaining parental affinity.
• Humanized Antibodies Custom antibody humanization via modernized CDR-grafting using human germline sequences to reduce immunogenicity while preserving parental affinity.
• Chimeric Antibodies Chimeric antibody production combining parental variable regions with human or other species constant regions, typically as a preliminary step prior to full humanization.
• Llama VHH Recombinant Antibodies Single-domain VHH (nanobody) antibody development and production from llama heavy-chain antibodies via phage display, for therapeutic and diagnostic applications.
• Veterinary Recombinant Antibodies Recombinant monoclonal antibody development for veterinary therapeutic applications via phage display from various species.
• Antibody Caninization Canine antibody engineering via CDR-grafting using canine germline sequences to reduce immunogenicity in dogs for veterinary immunotherapy applications.
• Antibody Felinization Feline antibody engineering via CDR-grafting using feline germline sequences to reduce immunogenicity in cats for veterinary immunotherapy applications.
• Recombinant Antibody Production (Transient Transfection) Recombinant antibody production in CHO cells via transient gene expression, achieving 50 to 300 mg/L yields within two weeks for early-stage material needs.
• Recombinant Antibody Production (Stable Cell Pool) Stable recombinant antibody production using piggyBac™ transposon technology for durable, high-yield expression in CHO-K1 cells.
• Hybridoma Production Large-scale antibody production and purification from hybridomas using in vitro methods (flask, HYPERFlask, CELLine, bioreactor) or in vivo (ascite) production.
• Antibody Characterization Comprehensive antibody analysis services including sequencing, affinity determination (BLI, SPR), cell banking, epitope mapping, and stability studies.
• Flow Cytometry Analysis Platform Flow cytometry-based antibody screening and characterization for evaluating antibody binding and functionality.
• Antibody Modification Antibody engineering and modification services including affinity maturation, conjugation (biotin, HRP, fluorochromes), and fragmentation (Fab, F(ab')2).
• Immunoassays End-to-end ELISA and Lateral Flow Immunoassay (LFIA) development and production services for in vitro diagnostic applications, including the Disp&FLOW® rapid test product line.
• ELISA & LFIA Development Custom ELISA and lateral flow rapid test development from feasibility studies through prototype optimization and validation, offered under results-commitment guarantees.
• ELISA & LFIA Production Industrial-scale production of ELISA and LFIA diagnostic kits under ISO 13485:2016 for human health, animal health and industrial applications.

Quantifiable outcome

• 97% customer satisfaction rate
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• Auvergne-Rhône-Alpes RegionsupportingOthersThe Quinthetic Library™ synthetic antibody libraries were developed with support from La Region Auvergne-Rhône-Alpes, providing regional government backing for innovation.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Sino Biological: Sino Biological combines a large recombinant antibody catalog with custom antibody development and ELISA/LFIA services. It competes with BIOTEM on both custom antibody services and immunoassay production, but operates at significantly larger scale with broader geographic reach including China and the US.
• Aldevron: Aldevron (now part of Danaher) is a biologics CDMO offering custom antibody and recombinant protein production services for research, diagnostic and clinical use. It overlaps with BIOTEM's recombinant antibody manufacturing and IVD supply services, but at larger GMP-certified scale.
• Bio-Rad Laboratories: Bio-Rad is a major life science tools provider with custom antibody and immunoassay services (through its Bio-Rad AbD Serotec / custom antibody capabilities). It competes with BIOTEM on research-grade custom antibody production for academic and industrial customers but operates a much broader life sciences portfolio.
• Eurofins Scientific: Eurofins operates a large global bioanalytical and contract research network including antibody and immunoassay services. It is a broader incumbent that overlaps with BIOTEM's IVD and immunology testing customers, especially in Europe, but serves a much wider portfolio of testing services.
• GenScript ProBio: GenScript ProBio is a major global bio-CDMO offering antibody discovery, engineering (humanization), and GMP manufacturing services. It directly competes with BIOTEM's fee-for-service antibody development and recombinant production offerings, but at a much larger scale and with GMP clinical-grade capacity BIOTEM lacks.

Regional players

• Syngene International: Syngene is an India-based integrated CRO/CDMO with biologics manufacturing including antibody services. It overlaps with BIOTEM on therapeutic antibody discovery and development but serves global biopharma from Asia rather than Europe.

Direct peers

• Creative Biolabs: Creative Biolabs is a US-based CRO specializing in custom antibody discovery (hybridoma, phage display) and engineering, including humanization and VHH/nanobody services. Its service catalog (mouse, rat, rabbit, llama, fully human, chimeric, humanized antibodies) maps almost one-to-one onto BIOTEM's offerings, making it one of the closest direct competitors.
• ProteoGenix: ProteoGenix is a France-based CRO offering custom antibody development, humanization, and recombinant production in mammalian cells. It is one of the closest geographic and service-line competitors to BIOTEM, particularly on therapeutic antibody humanization and recombinant antibody production.

Emerging players

• Abcam: Abcam is a leading antibody reagents supplier that also offers custom antibody production and licensing programs (now part of Danaher). It overlaps with BIOTEM's catalog antibody and IHC antibody products, though Abcam's primary model is catalog product sales versus BIOTEM's custom service model.
• AbCellera Biologics: AbCellera is an antibody discovery platform that combines proprietary screening technology with AI and a growing CDMO arm. While focused upstream on discovery rather than hybridoma, its antibody engineering and partner program compete with BIOTEM's therapeutic antibody humanization and recombinant production services for biotech customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/BIOTEM_Antibody

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOTEM